Swedish Heart Lung Foundation   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Stockholm Sweden (1904)

Organization Overview

First Clinical Trial
1995
NCT00389168
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Swedish Heart Lung Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Angina, Unstable (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Hypertension (Phase 3)

Infarction (Phase 4)

Influenza, Human (Phase 4)

Myocardial Infarction (Phase 4)

ST Elevation Myocardial Infarction (Phase 3)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 20